Literature DB >> 7737713

Reduction of salt intake during converting enzyme inhibitor treatment compared with addition of a thiazide.

D R Singer1, N D Markandu, F P Cappuccio, M A Miller, G A Sagnella, G A MacGregor.   

Abstract

A moderate reduction in salt intake lowers blood pressure in individuals with hypertension and improves blood pressure control in those taking a converting enzyme inhibitor. However, it is unclear how effective reduction of salt intake is compared with addition of other drugs, in particular, thiazide diuretics. We directly compared the separate effects on blood pressure of reducing sodium intake or adding a thiazide diuretic in the pressure of a converting enzyme inhibitor in a double-blind, randomized, crossover study. We studied 11 subjects with essential hypertension who had been taking 25 mg captopril twice daily for at least 1 month. In the double-blind study, after 1 month of captopril alone, supine blood pressure was 151 +/- 5/95 +/- 4 (SEM) mm Hg. With the addition of 25 mg hydrochlorothiazide once daily for 1 month, blood pressure fell to 137 +/- 5/87 +/- 3 mm Hg. When a moderate reduction in salt intake (from 206 +/- 26 to 109 +/- 20 mmol urinary sodium/24 h) was added to captopril for 1 month, blood pressure was reduced by a similar amount (to 137 +/- 4/90 +/- 3 mm Hg). Plasma potassium fell during the diuretic treatment (3.9 +/- 0.1 to 3.7 +/- 0.1 mmol/L, P < .05) but increased nonsignificantly during salt reduction (3.9 +/- 0.1 to 4.1 +/- 0.2 mmol/L). These results clearly demonstrate that moderate salt reduction, which can be easily achieved, is as effective as a thiazide diuretic in lowering blood pressure in the presence of a converting enzyme inhibitor and has the particular advantage that plasma potassium does not decrease.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7737713     DOI: 10.1161/01.hyp.25.5.1042

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  9 in total

1.  Salt--overwhelming evidence but still no action: can a consensus be reached with the food industry? CASH (Consensus Action on Salt and Hypertension)

Authors:  G A MacGregor; P S Sever
Journal:  BMJ       Date:  1996-05-18

2.  Salt supplementation blunts the blood pressure response to telmisartan with or without hydrochlorothiazide in hypertensive patients with type 2 diabetes.

Authors:  E I Ekinci; G Thomas; R J MacIsaac; C Johnson; C Houlihan; S Panagiotopoulos; E Premaratne; H Hao; S Finch; C O'Callaghan; G Jerums
Journal:  Diabetologia       Date:  2010-04-07       Impact factor: 10.122

3.  Impact of Hypertension on Early Renal Dysfunction in Japanese Prostate Cancer Patients Treated With Androgen Deprivation Therapy.

Authors:  Hiroshi Masuda; Masahiro Sugiura; Kyokusin Hou; Kazuhiro Araki; Satoko Kojima; Yukio Naya
Journal:  Cancer Diagn Progn       Date:  2021-07-03

4.  Difference in 24-hour urine sodium excretion between controlled and uncontrolled patients on antihypertensive drug treatment.

Authors:  Moo-Yong Rhee; Sang-Ho Jo; Ji-Hyun Kim; Kwang-Il Kim; Deuk-Young Nah; Sun-Woong Kim; Namyi Gu; Ki-Chul Sung; Kyung-Soon Hong; Eun-Joo Cho; Sim-Yeol Lee
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-06-27       Impact factor: 3.738

5.  Hypertension and end-organ disease in African Americans: case presentations.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

Review 6.  Obesity, kidney dysfunction, and inflammation: interactions in hypertension.

Authors:  John E Hall; Alan J Mouton; Alexandre A da Silva; Ana C M Omoto; Zhen Wang; Xuan Li; Jussara M do Carmo
Journal:  Cardiovasc Res       Date:  2021-07-07       Impact factor: 10.787

Review 7.  Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke.

Authors:  Sverre E Kjeldsen; Paulette A Lyle; Jorge R Kizer; Suzanne Oparil; Aud Høieggen; Ingrid Os
Journal:  Vasc Health Risk Manag       Date:  2007

8.  The influence of dietary sodium content on the pharmacokinetics and pharmacodynamics of fimasartan.

Authors:  Namyi Gu; Joo-Youn Cho; Kwang-Hee Shin; In-Jin Jang; Moo-Yong Rhee
Journal:  Drug Des Devel Ther       Date:  2016-04-19       Impact factor: 4.162

Review 9.  Meeting the challenge to improve the treatment of hypertension in blacks.

Authors:  Antonio Alberto Lopes; Sherman A James; Friedrich K Port; Akinlolu O Ojo; Lawrence Y Agodoa; Kenneth A Jamerson
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Nov-Dec       Impact factor: 3.738

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.